Cystinosin promotes melanoma development through ferroptosis via the GNMT/PARP1 pathway
Abstract
IntroductionCutaneous melanoma, one of the most aggressive and lethal skin cancers, is highly metastatic and often resistant to conventional therapies. This study aims to explore the biological effects of CTNS on melanoma and its underlying mechanisms, so as to identify a novel promising therapeutic target for melanoma treatment.MethodsBioinformatic analysis assessed CTNS expression and prognostic value in melanoma. qRTPCR, western blot and immunohistochemistry detected CTNS expression. CCK8, Transwell and wound healing assays evaluated cell proliferation and migration. A nude mouse subcutaneous xenograft model explored in vivo tumor growth. Flow cytometry, microplate reader, electron microscopy and ferrous probe assays measured cell cycle, apoptosis, ROS, GPX activity, MDA, ultrastructure and free iron. Western blot, coimmunoprecipitation and immunofluorescence verified ferroptosis signaling and protein interactions. Cytoplasmicnuclear fractionation, PCR and western blot clarified CTNSdependent regulation of GNMT nuclear localization and the CTNS/GNMT/PARP1 ferroptosis axis, validated by in vivo tumor assays.ResultsCTNS was upregulated in melanoma and predicted poor prognosis. CTNS knockdown suppressed melanoma migration and tumor growth, triggering ferroptosis evidenced by reduced GPX activity, elevated ROS, free iron and MDA, and typical mitochondrial ferroptotic morphology. CTNS depletion increased GNMT total and nuclear levels, downregulated PARP1, and decreased GPX4, ferritin and HIF1α; GNMT silencing rescued PARP1 reduction, while PARP1 overexpression reversed ferroptosis.DiscussionCTNS knockdown promotes GNMT nuclear accumulation, inhibits PARP1 expression, and consequently triggers ferroptosis in melanoma cells. Our findings suggest that CTNS merits further evaluation as a potential therapeutic target for patients with advanced melanoma.
Related
- CDCA5 promotes hepatocellular carcinoma progression by suppressing ferroptosis through PP2Ac/p53/STEAP3 signaling
- ALDH2 Suppresses Ferroptosis and Promotes Bortezomib Resistance in Multiple Myeloma Through the KEAP1-NRF2 Feedback Loop.
- UPF1-mediated mRNA decay promotes melanoma tumorigenesis through miR-101-3p-dependent destabilization of NANOS1.
- Mucolipin TRP Cation Channel 1 Depletion Promotes Gastric Cancer Cell Ferroptosis Through the AKT Pathway
- TPX2 promotes osteosarcoma progression by conferring ferroptosis resistance through the AURKA/NRF2 signaling axis
BibTeX
@article{li2026cystinosin,
title = {{Cystinosin promotes melanoma development through ferroptosis via the GNMT/PARP1 pathway}},
author = {Yanjun Li and Yaxin Guo and Hexiao Wang and Jun Yin and Suling Xu and Xinghua Gao},
journal = {Frontiers in Oncology},
year = {2026},
month = nov,
doi = {10.3389/fonc.2026.1970434},
url = {https://www.frontiersin.org/articles/10.3389/fonc.2026.1970434},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Cystinosin promotes melanoma development through ferroptosis via the GNMT/PARP1 pathway
AU - Yanjun Li
AU - Yaxin Guo
AU - Hexiao Wang
AU - Jun Yin
AU - Suling Xu
AU - Xinghua Gao
PY - 2026
DA - 2026/11/05
JO - Frontiers in Oncology
DO - 10.3389/fonc.2026.1970434
UR - https://www.frontiersin.org/articles/10.3389/fonc.2026.1970434
AB - IntroductionCutaneous melanoma, one of the most aggressive and lethal skin cancers, is highly metastatic and often resistant to conventional therapies. This study aims to explore the biological effects of CTNS on melanoma and its underlying mechanisms, so as to identify a novel promising therapeutic target for melanoma treatment.MethodsBioinformatic analysis assessed CTNS expression and prognostic value in melanoma. qRTPCR, western blot and immunohistochemistry detected CTNS expression. CCK8, Transwell and wound healing assays evaluated cell proliferation and migration. A nude mouse subcutaneous xenograft model explored in vivo tumor growth. Flow cytometry, microplate reader, electron microscopy and ferrous probe assays measured cell cycle, apoptosis, ROS, GPX activity, MDA, ultrastructure and free iron. Western blot, coimmunoprecipitation and immunofluorescence verified ferroptosis signaling and protein interactions. Cytoplasmicnuclear fractionation, PCR and western blot clarified CTNSdependent regulation of GNMT nuclear localization and the CTNS/GNMT/PARP1 ferroptosis axis, validated by in vivo tumor assays.ResultsCTNS was upregulated in melanoma and predicted poor prognosis. CTNS knockdown suppressed melanoma migration and tumor growth, triggering ferroptosis evidenced by reduced GPX activity, elevated ROS, free iron and MDA, and typical mitochondrial ferroptotic morphology. CTNS depletion increased GNMT total and nuclear levels, downregulated PARP1, and decreased GPX4, ferritin and HIF1α; GNMT silencing rescued PARP1 reduction, while PARP1 overexpression reversed ferroptosis.DiscussionCTNS knockdown promotes GNMT nuclear accumulation, inhibits PARP1 expression, and consequently triggers ferroptosis in melanoma cells. Our findings suggest that CTNS merits further evaluation as a potential therapeutic target for patients with advanced melanoma.
SN - 2234-943X
ER -